Johnson & Johnson (NYSE:JNJ) Shares Bought by Moss Adams Wealth Advisors LLC

Moss Adams Wealth Advisors LLC lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 8.1% during the first quarter, HoldingsChannel reports. The institutional investor owned 11,123 shares of the company’s stock after purchasing an additional 830 shares during the period. Moss Adams Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $1,845,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the business. Tallon Kerry Patrick acquired a new position in shares of Johnson & Johnson in the 4th quarter worth approximately $290,000. Capital & Planning LLC increased its position in shares of Johnson & Johnson by 13.6% in the fourth quarter. Capital & Planning LLC now owns 1,528 shares of the company’s stock worth $221,000 after acquiring an additional 183 shares in the last quarter. Brighton Jones LLC boosted its holdings in shares of Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after purchasing an additional 6,332 shares during the period. Union Bancaire Privee UBP SA acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth approximately $85,886,000. Finally, Money Concepts Capital Corp boosted its holdings in shares of Johnson & Johnson by 1.4% during the fourth quarter. Money Concepts Capital Corp now owns 41,682 shares of the company’s stock worth $6,028,000 after purchasing an additional 593 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ opened at $155.02 on Monday. The company has a market capitalization of $372.99 billion, a price-to-earnings ratio of 23.31, a P/E/G ratio of 2.56 and a beta of 0.42. The firm’s 50 day simple moving average is $153.59 and its 200 day simple moving average is $153.67. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $21.89 billion during the quarter, compared to analysts’ expectations of $21.65 billion. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 3.35%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson’s dividend payout ratio is presently 57.84%.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on JNJ shares. Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a research note on Thursday. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Wall Street Zen lowered shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 22nd. The Goldman Sachs Group raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their price target for the company from $157.00 to $172.00 in a report on Wednesday, April 9th. Finally, Morgan Stanley boosted their price target on shares of Johnson & Johnson from $164.00 to $169.00 and gave the company an “equal weight” rating in a report on Wednesday, April 16th. Eleven research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average target price of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.